previous
discov
one
particular
hlaa
mutant
enhanc
peptidespecif
cytotox
lymphocyt
ctl
recognit
vitro
compar
wildtyp
hlaa
mutant
contain
singl
amino
acid
substitut
histidin
leucin
posit
locat
peptidebind
groov
investig
effect
mutat
vivo
ctl
prime
took
advantag
technolog
hla
class
singlechain
trimer
sct
three
compon
involv
peptid
microglobulin
hla
class
heavi
chain
join
togeth
via
flexibl
linker
gener
recombin
adenoviru
express
sct
compris
influenza
matrix
protein
fmp
deriv
peptid
microglobulin
heavi
chain
hlaa
transgen
mice
immun
adenoviru
induct
peptidespecif
ctl
antitumor
immun
investig
clearli
shown
mutat
enabl
hlaa
sct
molecul
dramat
enhanc
vivo
prime
fmpspecif
ctl
protect
lethal
challeng
tumor
cell
express
fmp
data
present
first
evid
simpl
point
mutat
hla
class
heavi
chain
sct
benefici
improv
ctlbase
immunotherapi
prophylaxi
control
tumor
singlechain
hla
mutant
enhanc
ctl
prime
matsui
et
al
major
histocompat
complex
mhc
class
molecul
heterodimer
glycoprotein
compos
polymorph
heavi
chain
invari
play
essenti
role
cytotox
lymphocyt
ctl
mediat
immun
bind
natur
process
antigen
peptid
present
ctl
immun
surveil
sinc
ctl
play
major
role
specif
clearanc
neoplast
cell
virusinfect
cell
improv
mhc
class
present
peptidespecif
ctl
induct
key
issu
develop
prophylact
therapeut
vaccin
tumor
intracellular
pathogen
discoveri
peptidebind
groov
mhc
class
molecul
major
breakthrough
immunolog
groov
form
two
helic
domain
eightstrand
sheet
floor
includ
six
peptidebind
pocket
design
pocket
af
previous
construct
extens
librari
human
leukocyt
antigen
hla
mutant
differ
singl
amino
acid
substitut
almost
amino
acid
posit
peptidebind
groov
examin
whether
chang
affect
hlaa
peptidespecif
ctl
respons
mutat
littl
neg
effect
peptidespecif
ctl
kill
activ
peptidepuls
target
cell
express
mutant
molecul
howev
one
mutant
dramat
enhanc
present
exogen
load
peptid
peptidespecif
ctl
compar
wildtyp
wt
hlaa
molecul
hlaa
mutant
contain
amino
acid
substitut
histidin
leucin
posit
locat
helix
peptidebind
groov
expect
mutant
might
use
effici
induct
hlaa
peptidespecif
ctl
lead
develop
novel
ctlbase
vaccin
howev
appropri
method
verifi
hypothesi
time
later
technolog
mhc
class
singlechain
trimer
sct
develop
sct
polypeptid
three
compon
peptid
mhc
class
heavi
chain
join
togeth
via
flexibl
linker
sinc
peptid
coval
attach
sct
stabl
cell
surfac
nativ
mhc
class
ipeptid
complex
note
sct
could
effici
stimul
peptidespecif
ctl
vivo
follow
dna
vaccin
sctbase
vaccin
could
provid
protect
tumor
pathogen
preassembl
molecul
bypass
normal
antigen
process
pathway
henc
sct
resist
virusencod
immun
evas
protein
prevent
peptid
process
load
present
addit
sct
may
greatli
affect
aberr
antigen
process
present
machineri
frequent
observ
tumor
thu
approach
expect
applic
dna
vaccin
tumor
viral
infect
studi
took
advantag
sct
technolog
evalu
effect
mutat
vivo
prime
peptidespecif
ctl
examin
vivo
ctl
respons
hlaa
mice
design
hhd
mice
employ
hhd
mice
express
transgen
hhd
molecul
human
coval
link
chimer
heavi
chain
compos
hlaa
domain
b
transmembran
cytoplasm
domain
innat
b
mous
gene
disrupt
homolog
recombin
hhd
molecul
effici
util
hlaa
ctl
htlvtax
hivpol
crreleas
assay
data
shown
mean
sd
triplic
well
experi
repeat
three
time
p
p
compar
rmahhd
student
ttest
enhanc
peptidebind
rmashhd
cell
cultur
peptid
examin
surfac
express
hhd
flow
cytometri
experi
repeat
twice
similar
result
data
standard
rel
bind
shown
mean
sd
triplic
well
p
p
compar
rmashhd
student
ttest
e
ctl
recognit
variou
hhd
mutant
fmpspecif
ctl
line
examin
kill
activ
rma
express
hhd
mutant
variou
mutat
posit
presenc
nmoll
fmp
crreleas
assay
data
repres
one
three
independ
experi
data
standard
rel
lysi
shown
mean
sd
triplic
well
p
p
p
ns
signific
oneway
analysi
varianc
respons
hhd
mice
therefor
hhd
mice
use
versatil
preclin
anim
model
studi
hlaa
ctl
respons
vivo
prime
experi
gener
recombin
adenoviru
express
sct
compos
influenza
virusderiv
peptid
either
wt
hhd
hhd
mutat
hhd
mice
immun
adenovirus
effici
peptidespecif
ctl
induct
compar
variou
assay
clearli
demonstr
first
time
simpl
point
mutat
mhc
class
heavi
chain
sct
molecul
induc
enhanc
vivo
ctl
prime
antitumor
protect
enhanc
present
exogen
load
peptid
ctl
mutant
previou
studi
demonstr
mutant
hlaa
molecul
mutat
possess
uniqu
abil
enhanc
present
exogen
load
peptid
peptidespecif
ctl
confirm
result
hhd
system
firstli
construct
mutant
hhd
gene
could
gener
mutat
hhd
molecul
figur
b
invers
polymeras
chain
reaction
pcr
base
sitedirect
mutagenesi
gene
transfect
express
mous
lymphoma
rma
cell
express
level
mutant
molecul
cell
almost
equival
hhd
molecul
rma
cell
express
wt
hhd
rmahhd
test
abil
mutant
hlaa
peptidespecif
ctl
line
gener
hhd
mice
examin
kill
activ
rmahhd
presenc
synthet
peptid
variou
concentr
standard
crreleas
assay
consist
previou
data
cell
lyse
influenza
matrix
peptid
fmp
specif
ctl
much
lower
peptid
concentr
rmahhd
cell
figur
similar
result
obtain
differ
hlaa
peptid
deriv
human
papillomaviru
hpv
human
tlymphotrop
viru
htlv
tax
htlvtax
human
immunodefici
viru
hiv
pol
hivpol
figur
indic
phenomenon
peptidespecif
describ
previou
studi
peptidebind
studi
conduct
use
transport
associ
antigen
defici
cell
line
rma
express
hhd
rmashhd
shown
figur
effici
peptid
load
hhd
molecul
significantli
increas
mutat
suggest
improv
peptid
load
may
result
enhanc
present
exogen
peptid
ctl
mutat
figur
seri
amino
acid
substitut
posit
hhd
molecul
also
test
effect
peptid
present
fmp
specif
ctl
addit
three
mutat
involv
appar
enhanc
peptid
present
fmp
specif
ctl
respons
figur
contrast
sever
mutat
includ
impair
fmp
specif
ctl
recognit
data
suggest
effect
mutat
depend
amino
acid
substitut
histidin
data
show
function
phenotyp
mutat
hhd
system
like
equal
mutant
hlaa
mutat
describ
previous
construct
sct
well
document
sct
potent
stimul
peptidespecif
ctl
vivo
sct
polypeptid
compris
three
mhc
class
compon
includ
antigen
peptid
mhc
class
heavi
chain
attach
sequenti
flexibl
linker
given
uniqu
properti
mutant
hypothes
sct
could
prime
peptidespecif
ctl
vivo
effici
sct
compos
wt
hhd
prove
hypothesi
produc
sct
construct
consist
follow
element
begin
amino
terminu
leader
sequenc
fmp
peptid
first
flexibl
linker
residu
matur
portion
human
second
flexibl
linker
residu
final
heavi
chain
hhd
scthhd
molecul
figur
b
scthhd
construct
stabli
express
cell
line
rma
appar
increas
express
level
mhc
class
molecul
cell
surfac
comparison
rmashhd
absenc
exogen
peptid
figur
result
impli
scthhd
express
cell
surfac
even
absenc
endogen
peptid
suggest
sct
molecul
like
bypass
mhc
class
antigen
process
due
preassembl
form
previou
studi
dna
vaccin
employ
stimul
peptidespecif
ctl
mhc
class
sct
vivo
although
approach
sever
advantag
effici
ctl
induct
rel
weak
therefor
gener
recombin
adenoviru
express
either
scthhd
adscthhd
vivo
prime
studi
control
recombin
adenoviru
express
fulllength
influenza
matrix
protein
adfmp
use
viral
titer
accur
calcul
tissu
cultur
infecti
dose
tcid
evalu
effect
mutat
hhd
mice
immun
either
adscthhd
adfmp
wt
adenoviru
adwt
variou
dose
rang
tcid
mous
week
follow
immun
spleen
cell
prepar
stimul
vitro
fmp
examin
fmp
specif
kill
activ
crreleas
assay
figur
shown
figur
fmpspecif
ctl
induc
mice
immun
tcid
either
adfmp
adscthhd
inocul
dose
tcid
howev
percentag
ctlposit
mice
diminish
mice
vaccin
adfmp
adscthhd
respect
figur
contrast
mice
gener
fmpspecif
ctl
immun
tcid
figur
furthermor
even
lower
dose
tcid
prime
fmpspecif
ctl
immun
mice
wherea
fmpspecif
ctl
respons
detect
mice
inject
either
adfmp
adscthhd
lower
dose
figur
b
adwt
dose
test
elicit
fmpspecif
ctl
mice
figur
data
indic
prime
fmpspecif
ctl
mice
effici
adscthhd
adfmp
verifi
effect
mutat
vivo
ctl
assay
perform
figur
high
dose
tcid
mice
infect
either
adscthhd
gave
highest
specif
lysi
fmp
puls
splenocyt
adfmpinject
mice
reveal
slightli
lower
kill
activ
figur
importantli
agreement
data
crreleas
assay
figur
fmpspecif
ctl
activ
significantli
observ
mice
inject
lower
dose
tcid
figur
b
contrast
mice
infect
low
dose
either
adscthhd
adfmp
gener
fmpspecif
ctl
respons
figur
also
carri
intracellular
interferon
ifn
stain
cell
stimul
fmp
week
follow
immun
either
adwt
adfmp
adscthhd
variou
dose
splenic
lymphocyt
immun
mice
prepar
cultur
fmp
hour
cell
stain
surfac
express
peptideinduc
intracellular
express
inocul
dose
tcid
mice
infect
gener
substanti
number
cell
figur
b
dose
infect
either
adfmp
adscthhd
induc
high
percentag
cell
sever
mice
test
well
lower
dose
tcid
howev
mice
inject
either
adfmp
adscthhd
show
signific
percentag
cell
figur
contrast
figur
vaccin
enhanc
fmpspecif
ctl
induct
hhd
mice
per
group
immun
either
adwt
adfmp
adscthhd
variou
dose
week
follow
immun
spleen
cell
stimul
fmp
examin
fmpspecif
kill
activ
crreleas
assay
use
rmahhd
puls
without
fmp
target
percent
posit
mice
group
shown
mice
gener
rel
lysi
specif
lysi
peptidepuls
rmahhd
specif
lysi
unpuls
rmahhd
defin
posit
b
data
repres
mice
immun
adenoviru
dose
tcid
rmahhd
cell
puls
without
fmp
use
target
label
indic
data
three
differ
repres
mice
p
p
p
compar
rmahhd
puls
without
peptid
student
test
appar
induc
peptidedriven
cell
mice
tcid
figur
b
taken
togeth
data
indic
mutat
hhd
molecul
significantli
improv
efficaci
sct
prime
peptidespecif
ctl
vivo
provid
better
protect
tumor
challeng
adscthhd
next
perform
tumor
challeng
experi
immun
either
adwt
adfmp
adscthhd
hhd
mice
challeng
receiv
adopt
cell
transfer
carboxyfluorescein
diacet
succinimidyl
ester
cfse
label
rmahhd
tumor
cell
express
fulllength
fmp
rmahhdfmp
along
rmahhd
cell
intern
control
twelv
hour
later
lysi
specif
rmahhdfmp
cell
spleen
measur
flow
cytometri
viru
inocul
dose
tcid
statist
differ
specif
lysi
mice
either
adscthhdor
adfmpinject
mice
figur
howev
signific
differ
observ
inocul
dose
tcid
vaccin
gave
significantli
higher
clearanc
rmahhdfmp
tumor
cell
express
endogen
fmp
mice
adscthhd
adfmp
figur
b
next
hhd
mice
five
per
group
immun
either
adwt
adfmp
adscthhd
variou
dose
week
follow
immun
vivo
ctl
assay
perform
experi
repeat
twice
similar
result
data
shown
mean
sd
p
p
p
ns
signific
oneway
analysi
varianc
b
repres
data
shown
number
panel
indic
percentag
fmpspecif
lysi
l
unpuls
spleen
cell
label
low
concentr
cfse
h
peptidepuls
spleen
cell
label
high
concentr
cfse
imm
immun
figur
adwtinfect
mice
die
day
wherea
mani
mice
mice
surviv
day
tumor
inocul
hand
vaccin
tcid
either
adfmp
adscthhd
induc
suffici
protect
iv
challeng
high
dose
tumor
cell
figur
also
test
whether
vaccin
could
inhibit
growth
tumor
skin
end
hhd
mice
immun
variou
recombin
adenovirus
dose
tcid
inocul
subcutan
low
number
mous
rmahhdfmp
tumor
cell
vaccin
inhibit
tumor
growth
effici
adfmp
adscthhd
immun
adwt
effect
reduct
tumor
growth
figur
overal
data
demonstr
vaccin
provid
better
protect
tumor
challeng
adfmp
adscthhd
induct
fmp
specif
longlast
memori
ctl
mice
immun
low
dose
also
examin
whether
longlast
fmpspecif
ctl
could
elicit
hhd
mice
immun
low
dose
tcid
inocul
dose
neither
adscthhd
adfmp
induc
detect
fmpspecif
ctl
respons
mice
figur
day
follow
immun
crreleas
assay
perform
variou
effector
target
cell
e
ratio
shown
figur
fmp
specif
ctl
detect
mice
even
day
immun
mice
inject
adwt
data
indic
immun
low
dose
effect
gener
longlast
memori
ctl
mice
mutat
provid
hlaa
molecul
relev
hhd
molecul
uniqu
abil
improv
exogen
peptid
present
lead
enhanc
recognit
ctl
without
loss
specif
figur
phenomenon
peptidespecif
came
enhanc
affin
class
ipeptid
bind
figur
studi
clearli
shown
outstand
properti
advantag
vivo
prime
peptidespecif
ctl
induct
antitumor
immun
use
sct
technolog
recombin
adenoviru
hhd
system
short
demonstr
effect
prime
fmpspecif
ctl
respons
adscthhd
adfmp
hhd
mice
figur
furthermor
vaccin
induc
antitumor
immun
better
adscthhd
adfmp
figur
overal
data
strongli
suggest
may
possibl
develop
effici
vaccin
enhanc
protect
immun
tumor
andor
viru
simpli
introduc
point
mutat
mhc
class
heavi
chain
sct
last
two
decad
number
mutat
analys
mhc
class
molecul
perform
multipl
group
sever
amino
acid
posit
defin
critic
antigen
present
ctl
recognit
find
result
data
ctl
respons
abolish
impair
introduct
singl
amino
acid
substitut
particular
posit
mhc
class
heavi
chain
time
number
class
mutant
practic
impact
peptidespecif
ctl
respons
hand
mutant
involv
report
obvious
enhanc
ctl
recognit
anoth
exampl
mutant
hlaa
contain
mutat
glutamin
glutam
acid
posit
mutat
result
enhanc
bind
improv
antigen
recognit
cell
surfac
ctl
prime
vitro
histidin
posit
locat
helix
form
portion
wall
c
pocket
one
six
bind
pocket
within
peptidebind
groov
accord
crystallograph
analysi
howev
residu
appear
engag
direct
interact
peptid
sinc
posit
histidin
aspart
acid
hlaa
molecul
except
hlaa
whose
posit
asparagin
invari
residu
may
play
import
role
conform
stabil
common
hlaa
subtyp
encod
histidin
except
hlaa
use
aspart
acid
addit
hlab
molecul
sequenc
posit
aspart
acid
tyrosin
two
differ
group
found
ctl
recognit
present
slightli
impair
group
show
display
increas
ctl
recognit
interestingli
mutat
littl
effect
ctl
respons
mutat
impair
ctl
recognit
studi
figur
addit
three
mutant
enhanc
fmpspecif
ctl
respons
presenc
exogen
fmp
peptid
figur
unclear
present
four
particular
amino
acid
substitut
caus
enhanc
ctl
recognit
could
specul
mutat
may
provid
depth
c
pocket
usual
shallow
comparison
pocket
lead
increas
affin
peptid
bind
figur
contrast
exogen
peptid
previous
show
endogen
process
peptid
present
ctl
hlaa
mutat
accord
data
fmpspecif
ctl
could
recogn
either
cell
infect
influenza
viru
unpublish
observ
data
suggest
histidin
posit
might
play
critic
role
relat
format
er
peptideload
complex
antigen
process
idea
might
abl
explain
human
immun
system
evolv
incorpor
mutat
posit
increas
effici
antigen
present
mhc
class
molecul
sct
develop
hansen
et
al
sct
immunogen
stimul
peptidespecif
ctl
vivo
technolog
may
applic
dna
vaccin
viru
infect
tumor
take
advantag
attribut
examin
whether
mutant
potenti
vaccin
platform
immunotherapi
shown
figur
stimul
fmpspecif
ctl
hhd
mice
lower
viral
dose
adscthhd
adfmp
data
strongli
suggest
molecul
stabl
cell
surfac
scthhd
nativ
hhd
molecul
therebi
fmpspecif
ctl
gener
even
fewer
mhc
class
ipeptid
complex
per
cell
cell
surfac
mice
vaccin
sct
molecul
retain
coval
attach
peptid
origin
sct
suppos
steadier
cell
surfac
equival
nativ
class
molecul
make
potenti
immunogen
origin
sct
howev
linker
extend
cterminu
peptid
would
disrupt
f
pocket
anchor
peptid
peptidebind
groov
peptid
high
bind
affin
may
littl
affect
disrupt
howev
peptid
low
medium
bind
affin
incorpor
sct
assembl
may
much
less
effici
might
explain
current
data
show
adscthhd
drastic
superior
adfmp
vivo
ctl
prime
antitumor
protect
figur
sinc
substitut
enhanc
peptid
bind
hlaa
figur
mutat
would
diminish
neg
influenc
linker
peptid
anchor
elimin
detriment
effect
peptid
linker
hansen
et
al
attempt
improv
design
sct
engin
mhc
class
heavi
chain
focus
tyrosin
posit
heavi
chain
conserv
residu
creat
part
f
pocket
play
major
role
accommod
cterminu
peptid
peptidebind
groov
firstli
mutat
tyrosin
alanin
posit
heavi
chain
introduc
sct
compris
b
heavi
chain
ovalbumin
peptid
specul
would
partial
open
bind
groov
allow
better
fit
ctermin
linkerattach
peptid
inde
ovalbuminspecif
ctl
kill
target
cell
express
somewhat
better
express
origin
sct
nativ
b
without
mutat
unlik
figur
howev
noncoval
attach
nativ
b
mutant
mutat
exhibit
poor
peptid
bind
comparison
wt
nativ
b
indic
enhanc
mechan
ctl
recognit
differ
notabl
still
unclear
whether
effici
elicit
ovalbuminspecif
ctl
vivo
secondari
tyrosin
posit
mhc
class
heavi
chain
second
residu
first
linker
chang
cystein
form
new
disulfid
bond
two
cystein
residu
coval
trap
peptid
bind
groov
sct
disulfid
trap
particularli
use
rel
weak
bind
peptid
shown
dna
vaccin
disulfid
trap
enhanc
immun
respons
low
affin
peptid
vivo
howev
publish
inform
concern
function
comparison
disulfid
trap
addit
mutat
describ
also
introduc
sct
b
howev
present
data
elispot
analysi
show
predomin
wt
counterpart
vivo
prime
peptidespecif
ctl
mice
anyhow
introduct
mutat
disulfid
trap
andor
mutat
might
gener
synergist
effect
vivo
prime
peptidespecif
ctl
approach
also
benefici
improv
instabl
mhc
class
multim
compos
lower
affin
mhcpeptid
complex
enabl
make
comprehens
analys
ctl
respons
pathogen
tumor
strike
result
experi
mice
vaccin
even
low
dose
tcid
protect
subcutan
iv
challeng
rmahhdfmp
tumor
cell
figur
data
reveal
high
effici
induct
protect
antitumor
immun
suggest
great
potenti
improv
current
tumor
vaccin
strategi
addit
sct
valuabl
advantag
bypass
antigen
process
therefor
may
overcom
sever
immun
evas
strategi
tumor
block
antigen
process
pathway
shown
enhanc
peptid
load
molecul
peptidespecif
figur
howev
necessari
confirm
hlaa
peptid
format
would
behav
manner
fmp
particular
import
design
tumor
vaccin
mani
tumorderiv
peptid
usual
low
bind
affin
mhc
class
molecul
capac
bind
present
low
affin
epitop
remain
investig
howev
preliminari
data
show
mutat
enhanc
bind
ctl
recognit
tumor
peptid
includ
comparison
wt
counterpart
use
henc
possibl
assum
may
improv
bind
present
low
affin
epitop
includ
tumor
epitop
self
peptid
anoth
major
concern
whether
mutat
found
hla
class
allel
bai
data
conform
chang
shallow
c
pocket
might
key
import
conclus
clearli
extens
demonstr
first
time
introduct
singl
mutat
hlaa
sct
induc
enhanc
vivo
prime
peptidespecif
ctl
protect
antitumor
immun
novel
approach
might
serv
drive
forc
develop
effect
immunotherapi
tumor
pathogen
use
hlaa
doubl
knockout
mice
express
transgen
hlaa
monochain
design
hhd
human
coval
link
chimer
heavi
chain
compos
hlaa
domain
b
transmembran
cytoplasm
domain
figur
b
sevento
tenweekold
mice
use
experi
mice
hous
appropri
anim
care
facil
saitama
medic
univers
handl
accord
intern
guidelin
experi
anim
studi
approv
anim
research
committe
saitama
medic
univers
synthet
peptid
hlaa
epitop
use
follow
fmp
sequenc
gilgfvftl
sequenc
tihdiilecv
htlvtax
sequenc
llfgypvyv
hivpol
sequenc
ilkepvhgv
synthet
peptid
correspond
epitop
synthes
operon
biotechnolog
tokyo
japan
mous
lymphoma
cell
line
rma
b
rma
b
cultur
medium
sigmaaldrich
st
loui
mo
fc
sigmaaldrich
hhd
genetransfect
cell
line
rmahhd
rmashhd
previous
describ
maintain
contain
nacalai
tesqu
kyoto
japan
human
kidney
cell
line
cell
line
obtain
american
type
cultur
collect
atcc
rockvil
md
cell
line
provid
adeasi
adenovir
vector
system
agil
technolog
la
jolla
ca
cell
maintain
dmem
sigmaaldrich
supplement
fc
sigmaaldrich
spleen
cell
naiv
hhd
mice
prepar
puls
appropri
peptid
hour
irradi
gray
induct
longlast
memori
ctl
hhd
mice
six
per
group
immun
tcid
adwt
day
immun
spleen
cell
prepar
stimul
vitro
twice
peptidepuls
syngen
spleen
cell
crreleas
assay
carri
variou
e
ratio
use
rmahhd
cell
puls
without
fmp
target
label
indic
data
three
differ
repres
mice
repres
data
shown
mean
sd
triplic
well
p
p
p
compar
rmahhd
puls
without
peptid
student
ttest
peptidepuls
cell
adopt
transfer
iv
mice
cellsmous
week
spleen
cell
immun
mice
prepar
stimul
twice
three
time
peptidepuls
irradi
gray
syngen
spleen
cell
second
stimul
human
recombin
cetu
barkley
ca
ad
cultur
media
final
concentr
uml
peptidespecif
kill
activ
ctl
line
check
crreleas
assay
prior
experi
use
rmahhd
cell
puls
without
appropri
peptid
target
peptidespecif
ctl
line
use
investig
kill
activ
rma
rmahhd
rmahhd
mutant
presenc
absenc
appropri
peptid
variou
concentr
e
ratio
standard
crreleas
assay
cdna
encod
hhd
gene
gener
revers
transcriptas
pcr
total
rna
rmahhd
cell
addit
restrict
site
sequenc
end
hhd
cdna
subclon
nheihindiii
site
invitrogen
carlsbad
ca
express
vector
use
templat
construct
librari
mutant
hhd
gene
ligat
invers
pcrbase
sitedirect
mutagenesi
perform
use
kodplu
mutagenesi
kit
toyobo
osaka
japan
accord
manufactur
instruct
brief
method
requir
two
backtoback
primer
orient
revers
direct
amplifi
entir
plasmid
one
primer
contain
nucleotid
chang
caus
singl
amino
acid
substitut
posit
domain
hhd
reaction
templat
plasmid
dna
digest
dpni
recogn
g
atc
site
plasmid
dna
purifi
ordinari
host
e
coli
indigest
pcr
product
contain
nucleotid
substitut
recircular
polynucleotid
kinas
ligas
result
plasmid
transform
gener
differ
kind
hhd
plasmid
point
mutat
posit
histidin
alanin
cystein
aspart
acid
glutam
acid
phenylalanin
glycin
isoleucin
lysin
leucin
asparagin
glutamin
serin
threonin
valin
tyrosin
whole
nucleotid
sequenc
mutant
hhd
gene
confirm
dna
sequenc
servic
operon
biotechnolog
artifici
gene
encod
sct
hhd
link
fmp
peptid
scthhd
figur
b
synthes
operon
biotechnolog
gene
consist
leader
sequenc
human
follow
immedi
fmp
sequenc
linker
residu
g
first
linker
follow
human
matur
sequenc
second
linker
residu
g
hhd
sequenc
process
sct
gene
synthesi
xhoi
hindiii
site
sequenc
ad
end
respect
sct
gene
subclon
xhoi
hindiii
site
express
vector
invitrogen
nucleotid
substitut
caus
mutat
domain
hhd
creat
use
kodplu
mutagenesi
kit
toyobo
describ
construct
confirm
dna
sequenc
operon
biotechnolog
gene
encod
whole
fmp
influenza
viru
synthes
operon
biotechnolog
insert
bgliixhoi
site
express
vector
clontech
laboratori
mountain
view
ca
vector
allow
fmp
fuse
gfp
protein
cterminu
transfect
rma
cell
transfect
hhd
plasmid
electropor
gene
pulser
biorad
laboratori
hercul
ca
describ
rma
cell
also
electropor
select
nakarai
tesqu
final
concentr
mgml
transfect
analyz
surfac
hhd
express
flow
cytometri
facscanto
ii
bd
bioscienc
franklin
lake
nj
use
indirect
immunofluoresc
monoclon
antibodi
transfect
express
multipl
posit
peak
clone
limit
dilut
express
mutant
hhd
molecul
transfect
almost
equival
rmahhd
rmashhd
cell
rmahhd
cell
transfect
electropor
rmahhdfmp
select
hygromycin
b
nakarai
tesqu
final
concentr
mgml
cell
clone
confirm
express
gfpfuse
fmp
flow
cytometri
facscanto
tm
ii
bd
bioscienc
data
shown
recombin
adenoviru
express
sct
molecul
fmp
peptidelink
hhd
adscthhd
gener
use
adeasi
adenovir
vector
system
agil
technolog
describ
briefli
synthes
sct
gene
encod
sct
hhd
link
fmp
peptid
operon
biotechnolog
describ
insert
xhoihindiii
site
pshuttlecmv
vector
pshuttlecmvscthhd
point
mutat
construct
creat
use
kodplu
mutagenesi
kit
toyobo
describ
construct
confirm
dna
sequenc
operon
biotechnolog
shuttl
vector
pshuttlecmvscthhd
linear
pmei
new
england
biolab
hert
uk
transform
compet
cell
contain
adenovir
backbon
plasmid
vector
recombin
adenoviru
plasmid
digest
paci
new
england
biolab
transfect
cell
lipofectamin
invitrogen
day
follow
transfect
adenovirus
releas
cell
three
cycl
rapid
freez
thaw
viru
amplifi
cell
viral
titer
determin
calcul
tcid
cell
synthes
fmp
gene
use
construct
insert
bgliixhoi
site
vector
agil
technolog
recombin
adenoviru
express
fmp
adfmp
gener
use
adeasi
system
describ
vector
allow
fmp
protein
fuse
tag
sequenc
cterminu
therefor
western
blot
perform
describ
previous
detect
express
fmp
protein
cell
infect
adfmp
use
antiflag
mab
sigmaaldrich
data
shown
immun
mice
inject
intraperiton
ip
either
tcid
adenoviru
ml
phosphatebuff
salin
crreleas
assay
crreleas
assay
carri
describ
briefli
week
follow
immun
spleen
cell
immun
mice
stimul
gammairradi
syngen
spleen
cell
puls
appropri
peptid
week
use
effector
cell
figur
detect
memori
ctl
figur
spleen
cell
prepar
day
immun
stimul
twice
gammairradi
peptidepuls
syngen
spleen
cell
second
stimul
human
recombin
cetu
ad
cultur
media
final
concentr
uml
examin
variou
hhd
mutant
peptidespecif
ctl
employ
figur
target
rma
rmahhd
rmahhd
mutant
cell
label
na
cro
incub
radioact
supernat
count
result
calcul
mean
triplic
assay
percentspecif
lysi
calcul
accord
formula
specif
lysi
cpm
sampl
cpm
spontan
cpm
maximum
cpm
spontan
spontan
releas
repres
radioact
releas
target
cell
absenc
effector
maximum
releas
repres
radioact
releas
target
cell
lyse
triton
sigmaaldrich
fmpspecif
ctl
respons
variou
rmahhd
mutant
cell
standard
percent
rel
lysi
follow
formula
rel
lysi
specif
lysi
rmahhd
mutant
specif
lysi
rma
specif
lysi
rmahhd
specif
lysi
rma
bind
peptid
hhd
molecul
investig
cell
surfac
stabil
assay
describ
use
rmashhd
brief
rma
transfect
cultur
hour
co
incub
puls
peptid
variou
concentr
hour
incub
hour
peptidepuls
cell
stain
follow
fitclabel
goat
antimous
igg
antibodi
sigmaaldrich
mean
fluoresc
intens
mfi
cell
line
measur
flow
cytometri
facscanto
tm
ii
bd
bioscienc
standard
percent
cell
surfac
express
rel
rma
transfect
incub
overnight
follow
formula
rel
intracellular
cytokin
stain
intracellular
cytokin
stain
perform
describ
brief
week
follow
immun
spleen
cell
incub
fmp
hour
presenc
brefeldin
golgiplug
tm
bd
bioscienc
block
fc
receptor
cell
stain
fitcconjug
antimous
smonoclon
antibodi
mab
biolegend
san
diego
ca
follow
stain
intracellular
peconjug
mab
biolegend
wash
cell
flow
cytometr
analys
perform
vivo
ctl
assay
carri
describ
brief
naiv
spleen
cell
prepar
split
two
popul
one
popul
puls
fmp
label
cfse
molecular
probe
eugen
wherea
popul
label
cfse
equal
number
cell
popul
mix
togeth
adopt
transfer
iv
mice
mous
immun
adenoviru
week
earlier
tumor
challeng
experi
vivo
ctl
assay
tumor
cell
rmahhd
rmahhdfmp
cell
label
cfse
respect
equal
number
cell
cell
line
mix
togeth
total
cell
inject
iv
mous
immun
adenoviru
week
previous
hour
spleen
cell
prepar
treat
antifc
receptor
mab
biolegend
stain
peconjug
b
mab
biolegend
wash
b
cell
analyz
express
cfse
flow
cytometri
facscanto
tm
ii
bd
bioscienc
percentspecif
lysi
calcul
accord
formula
standard
vivo
ctl
assay
describ
ii
surviv
mice
ten
hhd
mice
per
group
immun
tcid
either
adwt
adfmp
adscthhd
week
follow
immun
mice
challeng
iv
rmahhdfmp
cell
mice
observ
surviv
day
iii
tumor
growth
mice
five
per
group
immun
tcid
either
adwt
adfmp
adscthhd
one
week
later
mice
inocul
subcutan
rmahhdfmp
cell
right
abdomin
flank
tumor
size
measur
everi
day
use
calip
two
perpendicular
diamet
tumor
volum
mm
calcul
use
follow
formula
tumor
volum
smaller
two
diamet
mice
kill
tumor
volum
grew
mm
statist
analys
two
group
perform
student
ttest
oneway
analysi
varianc
follow
post
hoc
test
carri
statist
analys
multipl
group
use
graph
pad
prism
softwar
graphpad
softwar
san
diego
ca
valu
p
consid
statist
signific
